Infirst's 'ChocoCough' gets £25 million backing
This article was originally published in Scrip
Executive Summary
Infirst Healthcare, a new company led by the former president of GlaxoSmithKline's European consumer healthcare business, has raised £25 million from Invesco Asset Management to launch products into the cough/cold and pain consumer healthcare markets.Infirst was spun out of the privatelyheld UK-based drug discovery group SEEK, which was founded in 2004 and previously known as PepTcell. SEEK and its US partner Pernix Therapeutics had initially hoped to find a partner to move the assets forward (scripintelligence.com, 28 March 2011).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.